Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) antibody (ab5473)
Key features and details
- Rabbit polyclonal to VEGF Receptor 2 (phospho Y1054 + Y1059)
- Suitable for: ICC/IF, WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) antibody
See all VEGF Receptor 2 primary antibodies -
Description
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1054 + Y1059) -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species ICC/IF HumanWB Human
-
Immunogen
Synthetic phospho peptide (Human)containing Tyrosines 1054 and 1059. This sequence is conserved in mouse and rat.
-
Positive control
- IF: VEGF treated HUVEC whole cells. WB: VEGF treated HUVEC, MDA-MB-231 and MCF7 whole cell extract.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.30
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.1% BSA, 50% Glycerol -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated VEGFR 2. The final product is generated by affinity chromatography using a VEGFR 2 derived peptide that is phosphorylated at Tyrosines 1054 and 1059. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab5473 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
| Application | Species |
|---|---|
| ICC/IF |
Human
|
| WB |
Human
|
| All applications |
Mouse
Rat
|
| Application | Abreviews | Notes |
|---|---|---|
| ICC/IF | (2) |
1/250.
|
| WB | (1) |
Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 200 kDa.
|
| Notes |
|---|
|
ICC/IF
1/250. |
|
WB
Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 200 kDa. |
Target
-
Function
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3791 Human
- Entrez Gene: 16542 Mouse
- Entrez Gene: 25589 Rat
- Omim: 191306 Human
- SwissProt: P35968 Human
- SwissProt: P35918 Mouse
- SwissProt: O08775 Rat
- Unigene: 479756 Human
see all -
Alternative names
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) antibody (ab5473)
Immunofluorescence analysis of HUVEC cells labelling VEGF Receptor 2 (phospho Y1054 + Y1059) (PAnel a: green) using ab5473 at 2 ug/ml in 0.1% BSA for 3 hours at room temperature, follwed by Alexa Fluor® 488-conjugated Goat anti-rabbit IgG polyclonal at 1/2000 dilution. Pbel b: Nuclei stained with DAPI (blue), Panel c: F-actin stained with Alexa Fluor® 555 Rhodamine Phalloidin (red), Panel d: Merged images. The images were captured at 60X magnification.
Prior antibody incubation, HUVEC (Human umbilical vein endothelial cell line) cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes and blocked with 1% BSA for 1 hour at room temperature, followed by treatment with 100 ng of VEGF for 30 minutes. Assay was done on 90% confluent log phase HUVEC cells.
-
Western blot - Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) antibody (ab5473)All lanes : Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) antibody (ab5473) at 1/1000 dilution
Lane 1 : HUVEC (Human umbilical vein endothelial cell line) whole cell extract with Skimmed milk
Lane 2 : HUVEC cells treated with 25ng/ml VEGF for 5 minutes with Skimmed milk
Lane 3 : MDA-MB-231 (human breast adenocarcinoma cell line) whole cell extract with Skimmed milk
Lane 4 : MCF7 (human breast adenocarcinoma cell line) whole cell extract with Skimmed milk
Lysates/proteins at 30 µg per lane.
Blocking peptides at 5 % per lane.
Secondary
All lanes : Goat anti-rabbit IgG HRP conjugate at 1/5000 dilutionA 130 kDa band corresponding to VEGFR (pYpY1054/1059) was observed across cell lines tested.
Protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel, XCell SureLock™ Electrophoresis System and Novex® Sharp Pre-Stained Protein Standard.
Resolved proteins were then transferred onto a nitrocellulose membrane by over night wet transfer.
Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate.
Protocols
References (26)
ab5473 has been referenced in 26 publications.
- Li L et al. Brivanib, a multitargeted small-molecule tyrosine kinase inhibitor, suppresses laser-induced CNV in a mouse model of neovascular AMD. J Cell Physiol 235:1259-1273 (2020). PubMed: 31270802
- Cho YR et al. A novel role for a-viniferin in suppressing angiogenesis by blocking the VEGFR-2/p70S6K signaling pathway. Phytother Res N/A:N/A (2020). PubMed: 32400050
- Jin B et al. Yangjing Capsule Can Improve the Function of the Testicular Angiogenesis through Activating VEGFA/eNOS Signaling Pathway. Evid Based Complement Alternat Med 2020:1957267 (2020). PubMed: 32382279
- Zhang Q et al. Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells. Gastroenterology 156:130-144.e10 (2019). PubMed: 30268789
- Zhang Q et al. Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma. Cells 8:N/A (2019). PubMed: 31121964
